ClinicalTrials.gg
CompletedNCT02175771Updated Nov 9, 2021Results posted

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

A Phase 3 interventional study of Fp MDPI and FS MDPI in Persistent Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 101 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
758
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
14th of 146
758 · median 100
Started
2014
with 8 others
Phase 3
35 of 147
none open now
Registered
107th of 147
by date
Lead sponsor
10 of 147
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 147 studies testing fluticasone in Asthma, this one is the 14th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2014, is one of 35 in phase 3, and was the 107th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the long-term safety of fluticasone propionate (Fp) inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation (FS) powder in 2 strengths when administered with the Teva multidose dry powder inhaler (MDPI) device over 26 weeks in patients with persistent asthma.

Read the detailed description

This was a stratified, randomized, open-label, active drug-controlled Phase 3 study.

Patients who met all of the inclusion criteria and none of the exclusion criteria at the screening visit completed a 14 day (±2 days) pretreatment run in period. During the run-in period, patients continued using their current asthma medications (ie, inhaled corticosteroid and/or other controller therapies) except for their SABA, which was replaced by the sponsor-provided albuterol (salbutamol) hydrofluoroalkane (HFA) inhaler to be used as needed for symptomatic relief of asthma symptoms during the run in and treatment periods.

Patients were assigned to inhaled corticosteroid (ICS) monotherapy or inhaled corticosteroid/long acting beta2 agonist (ICS/LABA) combination therapy and then to a mid- or high-treatment strength based on their current asthma maintenance therapy regimen. Patients in each strength of the ICS monotherapy cohort were randomly assigned in a 3:1 distribution to either the Fp MDPI or FLOVENT HFA treatment arm. Patients in each strength of the ICS/LABA combination cohort were randomly assigned in a 3:1 distribution to either the FS MDPI or ADVAIR DISKUS treatment arm. There was a total of 8 treatment arms following randomization.

03

Conditions studied

  • Persistent Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Best pre-bronchodilator (FEV1) of greater than 40% of their predicted normal value.
  2. Patients must have a treatment regimen that includes a short-acting β2 agonist (SABA) (albuterol) for use as needed and either an inhaled (ICS) or an ICS/long-acting β2 agonist (LABA) as a preventative treatment for a minimum of 8 weeks before the SV. Patients currently taking low-dose ICS without LABA are not eligible for this study. Patients currently taking low-dose ICS/LABA may only be entered into the mid ICS strength. All patients must have been maintained on a stable dose of ICS or ICS/LABA for 4 weeks prior to the SV (or pre-SV if necessary) at 1 qualifying doses
  3. To meet reversibility of disease criteria, the patient must demonstrate a ≥12% reversibility of FEV1 (and 200 mL for patients aged18 years and older) within 30 minutes following 4 inhalations of albuterol at the SV. Historic reversibility within the past 12 months of the SV may be used to meet this criterion.
  4. Written /assent is obtained. For adult patients (aged 18 years and older, or as applicable per local regulations), the written informed consent form (ICF) must be signed and dated by the patient before conducting any study-related procedure. For minor patients (aged 12 to 17 years, or as applicable per local regulations), the written ICF must be signed and dated by the parent/legal guardian and the written assent form must be signed and dated by the patient (if applicable) before conducting any study-related procedure. Note: Age requirements are as specified by local regulations.
  5. Outpatient >= 12 years of age on the date of consent/assent. .
  6. Asthma diagnosis: The patient has a diagnosis of asthma as defined by the National Institutes of Health (NIH). The asthma diagnosis has been present for a minimum of 3 months and has been stable (defined as no exacerbations and no changes in medication) for at least 30 days before providing informed consent.
  7. The patient is able to perform acceptable and repeatable spirometry.
  8. The patient is able to perform peak expiratory flow (PEF) with a handheld peak flow meter.
  9. The patient is able to use a metered-dose inhaler (MDI) device without a spacer device and a MDPI device.
  10. The patient is able to withhold (as judged by the investigator) his or her regimen of ICS or study drug, and rescue medication for at least 6 hours before the SV and before all treatment visits where spirometry is performed.
  11. The patient/parent/legal guardian/caregiver is capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements.
  12. SABAs: All patients must be able to replace their current SABA with albuterol/salbutamol HFA inhalation aerosol at the SV for use as needed for the duration of the study.
  13. Female patients may not be pregnant, breastfeeding, or attempting to become pregnant.

    • -Other criteria may apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  1. The patient has a history of a life-threatening asthma exacerbation that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures.
  2. The patient is pregnant or lactating, or plans to become pregnant during the study period or for 30 days after the study.
  3. The patient has participated as a randomized patient in any drug study within the 30 days preceding the SV (or prescreening visit, as applicable) or plans to participate in another investigational drug study at any time during this study.
  4. The patient has previously participated in an Fp MDPI or FS MDPI study.
  5. The patient has a known to any , salmeterol, or any of the in the study drug or rescue medication formulation (ie, lactose).
  6. The patient has been treated with any known strong cytochrome P450 (CYP) 3A4 inhibitors (eg, azole antifungals, ritonavir, or clarithromycin) within 30 days before the SV or plans to be treated with any strong inhibitor during the study.
  7. The patient has been treated with any of the prohibited medications during the prescribed (per protocol) before the SV.
  8. The patient currently smokes or has a smoking history of 10 pack-years or more (a pack-year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient may not have used tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco).
  9. The patient has a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that has not resolved at least 2 weeks before the SV.
  10. The patient has a history of alcohol or drug abuse within 2 years preceding the SV.
  11. The patient has had an asthma exacerbation requiring systemic corticosteroids within 30 days before the SV, or has had any hospitalization for asthma within 2 months before the SV.
  12. Initiation or dose escalation of immunotherapy (administered by any route) is planned during the study period. However, patients who initiated immunotherapy 90 days or more before the SV and have been on a stable (maintenance) dose for 30 days or more before the SV may be considered for inclusion.
  13. The patient has used medications within 4 weeks before the SV.
  14. The patient is unable to tolerate or unwilling to comply with the appropriate washout periods and withholding of all applicable medications. (Patients that require continuous treatment with β-blockers, monoamine oxidase inhibitors, tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids are excluded).
  15. The patient has untreated oral candidiasis at the SV. Patients with clinical visual evidence of oral candidiasis who agree to receive treatment and comply with appropriate medical monitoring may enter the study.
  16. The patient has a history of a positive test for , active virus, or infection.
  17. The patient is either an employee or an immediate relative of an employee of the clinical investigational center.
  18. A member of the patient's household is participating in the study at the same time. However, after the enrolled patient completes or discontinues participation in the study, another patient from the same household may be screened.
  19. The patient has a disease/condition that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.

    • Other criteria may apply, please contact the investigator for more information

Criteria for Randomization:

Patients were randomized into the study if they met all of the following criteria:

  1. The patient continued to be in general good health, meeting the entry criteria.
  2. The patient continued to have a predose/pre-albuterol at the randomization visit (RV) that was ≥40% of predicted normal.
  3. The patient had no abnormal laboratory test results or findings at the screening visit.
  4. The patient had no significant changes in asthma medications during run-in, excluding the albuterol/salbutamol HFA (90 mcg ex actuator) or equivalent used as rescue medication as supplied per protocol.
  5. The patient did not have a upper respiratory tract infection (URI) or lower respiratory tract infection (LRI) during the run in period. Patients who developed a URI or LRI during the run in period could be discontinued from the study and allowed to re-screen 2 weeks after resolution of symptoms.
  6. The patient had no asthma exacerbation during the run in period, defined as any worsening of asthma requiring any significant treatment other than rescue albuterol/salbutamol HFA (90 mcg ex actuator) or equivalent or the patient's run-in MDPI. This included requiring the use of systemic corticosteroids and/or emergency department (ED) visit or hospitalization or an increase in the patient's regularly prescribed nonsteroidal maintenance treatment. Urgent care/ED visits where the treatment was limited to a single dose of nebulized albuterol/salbutamol did not meet the criteria of an asthma exacerbation.
  7. The patient had no clinical visual evidence (on oropharyngeal examination) of oropharyngeal candidiasis.
  8. The patient did not experience an adverse event that would result in failure to continue to meet selection criteria.
  9. The patient did not use any of the prohibited concomitant medications during the run in period.
  10. The patient complied with completion of the daily diary, defined as follows:

    • completion of AM and PM asthma symptom scores on 4 or more of the 7 days immediately preceding the RV.
    • completion of rescue medication use (whether used or not) on 4 or more of the 7 days immediately preceding the RV.
    • completion of AM peak expiratory flow (PEF) measurements on 4 or more of the 7 days immediately preceding the RV.
    • recording of AM and PM asthma inhalation therapy use on 4 or more of the 7 days immediately preceding the RV.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
758 participants (actual)

Study arms

  • Experimental
    Fp MDPI 100 mcg

    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: Fp MDPI · Drug: albuterol/salbutamol HFA

  • Active comparator
    FLOVENT HFA 110 mcg

    Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: FLOVENT HFA · Drug: albuterol/salbutamol HFA

  • Experimental
    Fp MDPI 200 mcg

    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: Fp MDPI · Drug: albuterol/salbutamol HFA

  • Active comparator
    FLOVENT HFA 220 mcg

    Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: FLOVENT HFA · Drug: albuterol/salbutamol HFA

  • Experimental
    FS MDPI 100/12.5 mcg

    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: FS MDPI · Drug: albuterol/salbutamol HFA

  • Active comparator
    ADVAIR DISKUS 250/50 mcg

    Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: ADVAIR DISKUS · Drug: albuterol/salbutamol HFA

  • Experimental
    FS MDPI 200/12.5 mcg

    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: FS MDPI · Drug: albuterol/salbutamol HFA

  • Active comparator
    ADVAIR DISKUS 500/50 mcg

    Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: ADVAIR DISKUS · Drug: albuterol/salbutamol HFA

Interventions

  • Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient. During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening.

    Also known as: fluticasone propionate, inhaled corticosteroid

  • FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient. During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening.

    Also known as: fluticasone propionate, inhaled corticosteroid, Salmeterol xinafoate, β2 adrenoceptor agonist

  • FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate. During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening.

    Also known as: fluticasone propionate, inhaled corticosteroid

  • DrugADVAIR DISKUS

    ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient. During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening.

    Also known as: fluticasone propionate, inhaled corticosteroid, salmeterol xinafoate, β2 adrenoceptor agonist

  • Drugalbuterol/salbutamol HFA

    Drug page: Albuterol

    A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

    Also known as: ProAir HFA, short-acting β2-adrenergic agonists

06

What researchers measure

Primary outcomes

  1. Participants With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

    Time frame: Day 1 to Week 26 of the Treatment Period

Secondary outcomes

  1. Participants With Positive Swab Test Results for Oral Candidiasis

    Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at each visit by a qualified healthcare professional. Any visual evidence of oral candidiasis during the oropharyngeal exam was evaluated by obtaining and analyzing a swab of the suspect area. This outcomes indicates how many participants had positive swab test results. The total number of participants who had oropharyngeal exams at each timepoint are specified in the timepoint field. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Participants with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol.

    Time frame: Baseline (Day 1 pre-treatment), Weeks 2, 6, 10, 14, 18, 22 26, Endpoint

  2. Participants With Potentially Clinically Significant Abnormal Vital Signs During the Treatment Period

    Data represents participants with potentially clinically significant (PCS) vital sign values during the Treatment period. Significance criteria: * Systolic blood pressure - high: \>=180 and increase \>=20 mmHg * Systolic blood pressure - low: \<=90 and decrease \>=20 mmHg * Diastolic blood pressure - high: \>=105 and increase of \>=15 mmHg * Diastolic blood pressure - low: \<=50 and decrease of \>=15 mmHg * Pulse - high: \>=120 and increase of \>= 15 beats/minute from baseline * Pulse - low: \<=50 and decrease of \>=15 beats/minute

    Time frame: Baseline (Day 1 pre-treatment), Weeks 2, 6, 10, 14, 18, 22 26, Endpoint

  3. Shifts From Baseline to Endpoint in Electrocardiogram (ECG) Findings

    A 12 lead ECG was conducted at the screening visit and week 26 or the early termination visit. A qualified physician at a central diagnostic center was responsible for interpreting the ECG. The worst post-baseline finding for the participant is summarized. Endpoint refers to the last observation carried forward.

    Time frame: Screening (Day -14), Endpoint (week 26 if study was completed)

  4. Analysis of 24-Hour Urine Cortisol Free Over the 26-Week Treatment Period

    Samples for 24-hour urine cortisol were collected at baseline (Day 1, pretreatment), and Weeks 14 and 26. For participants requiring early termination (ET), this evaluation was performed at the ET visit. For participants requiring ET for safety reasons, the visit was not delayed in order to collect the 24-hour urine cortisol. The analysis is based on a mixed model for repeated measures (MMRM) model with adjustment for visit, treatment, and a treatment\*visit interaction. The urine cortisol result is log transformed prior to analysis and the results are back transformed after modeling. An unstructured covariance matrix is used in the MMRM model.

    Time frame: Baseline (Day 1, pre-treatment), Weeks 14 and 26 and early termination visit if applicable

  5. Change From Baseline in Trough Forced Expiratory Volume in 1 Minute (FEV1) Over the 26-Week Treatment Period

    Spirometry measurements were obtained before the AM dose of study drug for the randomization visit (Day 1), at each of the treatment visits and at the early termination visit if applicable. At each visit where FEV1 was assessed, the highest acceptable results from each session were recorded. The analysis is based on a mixed model for repeated measures (MMRM) with adjustment for baseline FEV1, sex, age, (pooled) investigational center, visit, treatment, and treatment-by-visit. An unstructured covariance matrix is used in the MMRM model.

    Time frame: Baseline (Day 1 pre-treatment), Weeks 2, 6, 10, 14, 18, 22 26, early termination visit if applicable

07

Results

Posted Apr 14, 2017

Participant flow

Of the 1087 patients screened, 758 patients at 103 investigational centers in the US met entry criteria. 331 patients were not enrolled: 267 due to inclusion/exclusion criteria, 21 withdrew consent, 9 were lost to follow up, 4 had an adverse event, and 30 patients had reason of 'other' or missing.

Run-In Period (Pre-assignment)
Participant flow — Run-In Period (Pre-assignment)
MilestoneEnrolled PatientsFp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcg
Started75800000000
Completed67400000000
Not completed8400000000
Withdrew: Randomization criteria not met2300000000
Withdrew: Exclusion criteria met2000000000
Withdrew: Withdrawal by subject1100000000
Withdrew: Adverse event900000000
Withdrew: Inclusion criteria not met700000000
Withdrew: Lost to follow-up600000000
Withdrew: Other800000000
Treatment Period
Participant flow — Treatment Period
MilestoneEnrolled PatientsFp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcg
Started012742126411204113344
Completed011135113361103611638
Not completed0167135105176
Withdrew: Adverse event021113201
Withdrew: Withdrawal by subject093624292
Withdrew: Noncompliance012000001
Withdrew: Protocol violation000000010
Withdrew: Disease progression000000020
Withdrew: Lost to follow-up031312122
Withdrew: Lack of efficacy000001010
Withdrew: Other010310020

Outcome measures

PrimaryParticipants With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

Time frame:
Day 1 to Week 26 of the Treatment Period
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
ParticipantsFp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcg
>=1 TEAE8529832992298630
>=1 severe TEAE8311381123
>=1 treatment-related TEAE1026594118
>=1 severe treatment-related TEAE00000000
>=1 serious TEAE728362133
>=1 TEAE leading to withdrawal21013201
>=1 nonserious TEAE8527822991288529
>=1 TEAE resulting in death00000000
SecondaryParticipants With Positive Swab Test Results for Oral Candidiasis

Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at each visit by a qualified healthcare professional. Any visual evidence of oral candidiasis during the oropharyngeal exam was evaluated by obtaining and analyzing a swab of the suspect area. This outcomes indicates how many participants had positive swab test results. The total number of participants who had oropharyngeal exams at each timepoint are specified in the timepoint field. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Participants with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol.

Time frame:
Baseline (Day 1 pre-treatment), Weeks 2, 6, 10, 14, 18, 22 26, Endpoint
Reported as:
Count of participants · Participants
Participants With Positive Swab Test Results for Oral Candidiasis
ParticipantsFp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcg
Baseline (n=127, 42, 124, 41, 120, 41, 133, 44)20000000
Week 2 (n=123, 42, 123, 40, 117, 39, 131, 43)20101012
Week 6 (n=119, 41, 119, 40, 115, 39, 125, 43)10001210
Week 10 (n=119, 37, 118, 39, 115, 39, 120, 40)00111101
Week 14 (n=116, 36, 115, 38, 113, 38, 120, 41)10112011
Week 18 (n=111, 37, 115, 38, 109, 38, 117, 40)10110100
Week 22 (n=110, 36, 113, 36, 110, 37, 116, 38)10111022
Week 26 (n=111, 35, 113, 36, 110, 36, 116, 38)10110100
Endpoint (n=125, 42, 123, 41, 119, 40, 132, 44)10110100
SecondaryParticipants With Potentially Clinically Significant Abnormal Vital Signs During the Treatment Period

Data represents participants with potentially clinically significant (PCS) vital sign values during the Treatment period. Significance criteria: * Systolic blood pressure - high: \>=180 and increase \>=20 mmHg * Systolic blood pressure - low: \<=90 and decrease \>=20 mmHg * Diastolic blood pressure - high: \>=105 and increase of \>=15 mmHg * Diastolic blood pressure - low: \<=50 and decrease of \>=15 mmHg * Pulse - high: \>=120 and increase of \>= 15 beats/minute from baseline * Pulse - low: \<=50 and decrease of \>=15 beats/minute

Time frame:
Baseline (Day 1 pre-treatment), Weeks 2, 6, 10, 14, 18, 22 26, Endpoint
Reported as:
Count of participants · Participants
Participants With Potentially Clinically Significant Abnormal Vital Signs During the Treatment Period
ParticipantsFp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcg
>=1 abnormality50012020
Systolic blood pressure - high00000000
Systolic blood pressure - low10001000
Diastolic blood pressure - high10000010
Diastolic blood pressure - low10011010
Pulse - high10000000
Pulse - low10000000
SecondaryShifts From Baseline to Endpoint in Electrocardiogram (ECG) Findings

A 12 lead ECG was conducted at the screening visit and week 26 or the early termination visit. A qualified physician at a central diagnostic center was responsible for interpreting the ECG. The worst post-baseline finding for the participant is summarized. Endpoint refers to the last observation carried forward.

Time frame:
Screening (Day -14), Endpoint (week 26 if study was completed)
Reported as:
Count of participants · Participants
Shifts From Baseline to Endpoint in Electrocardiogram (ECG) Findings
ParticipantsFp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcg
Baseline normal - Endpoint normal89319333903010128
Baseline normal - Endpoint abnormal85619283
Baseline abnormal - Endpoint normal414212294
Baseline abnormal - Endpoint abnormal1121335474
SecondaryAnalysis of 24-Hour Urine Cortisol Free Over the 26-Week Treatment Period

Samples for 24-hour urine cortisol were collected at baseline (Day 1, pretreatment), and Weeks 14 and 26. For participants requiring early termination (ET), this evaluation was performed at the ET visit. For participants requiring ET for safety reasons, the visit was not delayed in order to collect the 24-hour urine cortisol. The analysis is based on a mixed model for repeated measures (MMRM) model with adjustment for visit, treatment, and a treatment\*visit interaction. The urine cortisol result is log transformed prior to analysis and the results are back transformed after modeling. An unstructured covariance matrix is used in the MMRM model.

Time frame:
Baseline (Day 1, pre-treatment), Weeks 14 and 26 and early termination visit if applicable
Reported as:
Geometric mean · mcg/24 hours
Analysis of 24-Hour Urine Cortisol Free Over the 26-Week Treatment Period
mcg/24 hoursFp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcg
Analysis of 24-Hour Urine Cortisol Free Over the 26-Week Treatment Period18.45 (15.77 to 21.58)13.94 (10.67 to 18.22)14.14 (12.23 to 16.34)17.50 (13.40 to 22.85)17.56 (15.13 to 20.38)18.29 (14.07 to 23.77)13.02 (11.23 to 15.09)15.42 (12.27 to 19.38)
Statistical analysis
  • Fp MDPI 100 mcg vs FLOVENT HFA 110 mcg · Geometric mean ratio: 1.32 · 90% CI 1.02 to 1.72Fp MDPI / FLOVENT HFA
  • Fp MDPI 200 mcg vs FLOVENT HFA 220 mcg · Geometric mean ratio: 0.81 · 90% CI 0.63 to 1.04Fp MDPI / FLOVENT HFA
  • FS MDPI 100/12.5 mcg vs ADVAIR DISKUS 250/50 mcg · Geometric mean ratio: 0.96 · 90% CI 0.75 to 1.24FS MDPI / ADVAIR DISKUS
  • FS MDPI 200/12.5 mcg vs ADVAIR DISKUS 500/50 mcg · Geometric mean ratio: 0.84 · 90% CI 0.67 to 1.06FS MDPI / ADVAIR DISKUS
SecondaryChange From Baseline in Trough Forced Expiratory Volume in 1 Minute (FEV1) Over the 26-Week Treatment Period

Spirometry measurements were obtained before the AM dose of study drug for the randomization visit (Day 1), at each of the treatment visits and at the early termination visit if applicable. At each visit where FEV1 was assessed, the highest acceptable results from each session were recorded. The analysis is based on a mixed model for repeated measures (MMRM) with adjustment for baseline FEV1, sex, age, (pooled) investigational center, visit, treatment, and treatment-by-visit. An unstructured covariance matrix is used in the MMRM model.

Time frame:
Baseline (Day 1 pre-treatment), Weeks 2, 6, 10, 14, 18, 22 26, early termination visit if applicable
Reported as:
Least squares mean · liters
Change From Baseline in Trough Forced Expiratory Volume in 1 Minute (FEV1) Over the 26-Week Treatment Period
litersFp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcg
Change From Baseline in Trough Forced Expiratory Volume in 1 Minute (FEV1) Over the 26-Week Treatment Period0.062 ± 0.02430.053 ± 0.04150.077 ± 0.02460.090 ± 0.04150.116 ± 0.02510.117 ± 0.04190.100 ± 0.02350.041 ± 0.0399
Statistical analysis
  • Fp MDPI 100 mcg vs FLOVENT HFA 110 mcg · mixed model for repeated measures · p = 0.8451 · Lsm difference: 0.009 · 95% CI -0.084 to 0.103Fp MDPI / FLOVENT HFA
  • Fp MDPI 200 mcg vs FLOVENT HFA 220 mcg · mixed model for repeated measures · p = 0.7877 · Lsm difference: -0.013 · 95% CI -0.107 to 0.081Fp MDPI / FLOVENT HFA
  • FS MDPI 100/12.5 mcg vs ADVAIR DISKUS 250/50 mcg · mixed model for repeated measures · p = 0.9966 · Lsm difference: 0.000 · 95% CI -0.095 to 0.095FS MDPI / ADVAIR DISKUS
  • FS MDPI 200/12.5 mcg vs ADVAIR DISKUS 500/50 mcg · mixed model for repeated measures · p = 0.2056 · Lsm difference: 0.059 · 95% CI -0.032 to 0.150FS MDPI / ADVAIR DISKUS

Adverse events

Collected over Day 1 to Week 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADVAIR DISKUS 250/50 mcg0/41 (0%)2/41 (4.9%)22/41 (53.7%)
ADVAIR DISKUS 500/50 mcg0/44 (0%)3/44 (6.8%)23/44 (52.3%)
FLOVENT HFA 110 mcg0/42 (0%)2/42 (4.8%)24/42 (57.1%)
FLOVENT HFA 220 mcg0/41 (0%)3/41 (7.3%)25/41 (61%)
FS MDPI 100/12.5 mcg0/120 (0%)6/120 (5%)70/120 (58.3%)
FS MDPI 200/12.5 mcg0/133 (0%)13/133 (9.8%)68/133 (51.1%)
Fp MDPI 100 mcg0/127 (0%)7/127 (5.5%)65/127 (51.2%)
Fp MDPI 200 mcg0/125 (0%)8/125 (6.4%)55/125 (44%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventADVAIR DISKUS 250/50 mcgADVAIR DISKUS 500/50 mcgFLOVENT HFA 110 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgFS MDPI 200/12.5 mcgFp MDPI 100 mcgFp MDPI 200 mcg
AsthmaRespiratory, thoracic and mediastinal disorders1/412/440/420/413/1208/1336/1274/125
Atrial tachycardiaCardiac disorders0/410/440/421/410/1200/1330/1270/125
Device dislocationGeneral disorders0/410/440/421/410/1200/1330/1270/125
CellulitisInfections and infestations0/410/440/421/410/1200/1330/1270/125
Wound dehiscenceInjury, poisoning and procedural complications0/410/440/421/410/1200/1330/1270/125
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/410/440/420/410/1200/1330/1270/125
FallInjury, poisoning and procedural complications0/410/441/420/410/1200/1330/1270/125
Hip fractureInjury, poisoning and procedural complications0/410/441/420/410/1200/1330/1270/125
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/410/441/420/410/1200/1330/1270/125
Deep vein thrombosisVascular disorders0/410/441/420/410/1200/1330/1270/125
Most frequent other events
Showing 10 of 14
Most frequent other events
EventADVAIR DISKUS 250/50 mcgADVAIR DISKUS 500/50 mcgFLOVENT HFA 110 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgFS MDPI 200/12.5 mcgFp MDPI 100 mcgFp MDPI 200 mcg
Upper respiratory tract infectionInfections and infestations9/416/4412/428/4121/12024/13323/12717/125
SinusitisInfections and infestations4/418/443/423/419/12014/13315/1276/125
NasopharyngitisInfections and infestations4/414/447/425/4115/12012/13317/12713/125
InfluenzaInfections and infestations2/411/442/425/417/1203/13310/1278/125
Oral candidiasisInfections and infestations2/415/440/425/415/1205/1336/1275/125
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/414/445/421/417/1209/13313/1276/125
CoughRespiratory, thoracic and mediastinal disorders2/411/443/424/4114/1208/13310/12713/125
HeadacheNervous system disorders4/412/442/421/419/1203/1335/1276/125
Back painMusculoskeletal and connective tissue disorders2/410/440/423/411/1203/1331/1271/125
Rhinitis allergicRespiratory, thoracic and mediastinal disorders3/410/440/421/417/1202/1331/1272/125

Baseline characteristics

Safety population which included all randomized participants who received at least 1 dose of randomized study drug

Age, Customized
Age, Customized(Participants)Fp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcgTotal
Adolescents (12-17 years)1971631359173
Adults (18-64 years)96329635943110641531
Adults (65+ years)12312313518268
Missing002000002
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Fp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcgTotal
Male4916461636216121266
Female7826782584207223406
Missing002000002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcgTotal
Not Hispanic or Latino1183910033993611239576
Hispanic or Latino9324821520595
Unknown000000101
Missing002000002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcgTotal
White11026993699329531528
Black or African American16132251993112127
Asian111020409
American Indian or Alaskan Native010000203
Pacific Islander002000013
Other010000102
Missing002000002
History of Smoking
History of Smoking(Participants)Fp MDPI 100 mcgFLOVENT HFA 110 mcgFp MDPI 200 mcgFLOVENT HFA 220 mcgFS MDPI 100/12.5 mcgADVAIR DISKUS 250/50 mcgFS MDPI 200/12.5 mcgADVAIR DISKUS 500/50 mcgTotal
Prior smoker2610205237248123
No tobacco use1013210636973410936551
08

Study locations

101 sites
  • Teva Investigational Site 12068
    Birmingham, Alabama, United States
  • Teva Investigational Site 12112
    Mobile, Alabama, United States
  • Teva Investigational Site 12130
    Pell City, Alabama, United States
  • Teva Investigational Site 12119
    Little Rock, Alaska, United States
  • Teva Investigational Site 12076
    Phoenix, Arizona, United States
  • Teva Investigational Site 12135
    Scottsdale, Arizona, United States
  • Teva Investigational Site 12132
    Tucson, Arizona, United States
  • Teva Investigational Site 12102
    Fountain Valley, California, United States
  • Teva Investigational Site 12104
    Fresno, California, United States
  • Teva Investigational Site 12123
    Fullerton, California, United States
  • Teva Investigational Site 12103
    Huntington Beach, California, United States
  • Teva Investigational Site 12073
    Long Beach, California, United States
  • Teva Investigational Site 12077
    Mission Viejo, California, United States
  • Teva Investigational Site 12098
    Napa, California, United States
  • Teva Investigational Site 12149
    Northridge, California, United States
  • Teva Investigational Site 12081
    Orange, California, United States
  • Teva Investigational Site 12100
    Rancho Mirage, California, United States
  • Teva Investigational Site 12133
    Riverside, California, United States
  • Teva Investigational Site 12146
    Riverside, California, United States
  • Teva Investigational Site 12075
    Rolling Hills Estates, California, United States
  • Teva Investigational Site 12074
    San Diego, California, United States
  • Teva Investigational Site 12150
    San Diego, California, United States
  • Teva Investigational Site 12064
    San Jose, California, United States
  • Teva Investigational Site 12061
    Stockton, California, United States
  • Teva Investigational Site 12141
    Walnut Creek, California, United States
  • Teva Investigational Site 12043
    Denver, Colorado, United States
  • Teva Investigational Site 12051
    Denver, Colorado, United States
  • Teva Investigational Site 12091
    Waterbury, Connecticut, United States
  • Teva Investigational Site 12078
    Fort Lauderdale, Florida, United States
  • Teva Investigational Site 12140
    Hialeah, Florida, United States
  • Teva Investigational Site 12066
    Kissimmee, Florida, United States
  • Teva Investigational Site 12120
    Miami, Florida, United States
  • Teva Investigational Site 12127
    Miami, Florida, United States
  • Teva Investigational Site 12148
    Miami, Florida, United States
  • Teva Investigational Site 12114
    Ocala, Florida, United States
  • Teva Investigational Site 12055
    Sarasota, Florida, United States
  • Teva Investigational Site 12048
    Tallahassee, Florida, United States
  • Teva Investigational Site 12122
    Tamarac, Florida, United States
  • Teva Investigational Site 12086
    Winter Park, Florida, United States
  • Teva Investigational Site 12111
    Gainesville, Georgia, United States
  • Teva Investigational Site 12070
    Lawrenceville, Georgia, United States
  • Teva Investigational Site 12072
    Marietta, Georgia, United States
  • Teva Investigational Site 12106
    Coeur d'Alene, Idaho, United States
  • Teva Investigational Site 12117
    Eagle, Idaho, United States
  • Teva Investigational Site 12065
    River Forest, Illinois, United States
  • Teva Investigational Site 12059
    Shiloh, Illinois, United States
  • Teva Investigational Site 12056
    Overland Park, Kansas, United States
  • Teva Investigational Site 12138
    Fort Mitchell, Kentucky, United States
  • Teva Investigational Site 12092
    Owensboro, Kentucky, United States
  • Teva Investigational Site 12087
    Covington, Louisiana, United States
  • Teva Investigational Site 12095
    Bangor, Maine, United States
  • Teva Investigational Site 12042
    Baltimore, Maryland, United States
  • Teva Investigational Site 12124
    Baltimore, Maryland, United States
  • Teva Investigational Site 12052
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 12139
    Minneapolis, Minnesota, United States
  • Teva Investigational Site 12137
    Plymouth, Minnesota, United States
  • Teva Investigational Site 12079
    Columbia, Missouri, United States
  • Teva Investigational Site 12067
    Rolla, Missouri, United States
  • Teva Investigational Site 12057
    Saint Louis, Missouri, United States
  • Teva Investigational Site 12060
    Saint Louis, Missouri, United States
  • Teva Investigational Site 12108
    Saint Louis, Missouri, United States
  • Teva Investigational Site 12128
    Warrensburg, Missouri, United States
  • Teva Investigational Site 12136
    Bellevue, Nebraska, United States
  • Teva Investigational Site 12115
    Las Vegas, Nevada, United States
  • Teva Investigational Site 12131
    Las Vegas, Nevada, United States
  • Teva Investigational Site 12126
    Ocean City, New Jersey, United States
  • Teva Investigational Site 12129
    Verona, New Jersey, United States
  • Teva Investigational Site 12058
    Rochester, New York, United States
  • Teva Investigational Site 12113
    Rockville Centre, New York, United States
  • Teva Investigational Site 12047
    Charlotte, North Carolina, United States
  • Teva Investigational Site 12085
    Charlotte, North Carolina, United States
  • Teva Investigational Site 12144
    Winston-Salem, North Carolina, United States
  • Teva Investigational Site 12053
    Canton, Ohio, United States
  • Teva Investigational Site 12094
    Cincinnati, Ohio, United States
  • Teva Investigational Site 12105
    Cincinnati, Ohio, United States
  • Teva Investigational Site 12107
    Sylvania, Ohio, United States
  • Teva Investigational Site 12069
    Tiffin, Ohio, United States
  • Teva Investigational Site 12045
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 12080
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 12083
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 12062
    Eugene, Oregon, United States
  • Teva Investigational Site 12097
    Medford, Oregon, United States
  • Teva Investigational Site 12049
    Portland, Oregon, United States
  • Teva Investigational Site 12134
    Bryn Mawr, Pennsylvania, United States
  • Teva Investigational Site 12090
    Philadelphia, Pennsylvania, United States
  • Teva Investigational Site 12089
    Providence, Rhode Island, United States
  • Teva Investigational Site 12088
    Warwick, Rhode Island, United States
  • Teva Investigational Site 12096
    Charleston, South Carolina, United States
  • Teva Investigational Site 12147
    Spartanburg, South Carolina, United States
  • Teva Investigational Site 12121
    Dallas, Texas, United States
  • Teva Investigational Site 12099
    El Paso, Texas, United States
  • Teva Investigational Site 12071
    Live Oak, Texas, United States
  • Teva Investigational Site 12054
    San Antonio, Texas, United States
  • Teva Investigational Site 12145
    Waco, Texas, United States
  • Teva Investigational Site 12046
    Murray, Utah, United States
  • Teva Investigational Site 12041
    South Burlington, Vermont, United States
  • Teva Investigational Site 12125
    Richmond, Virginia, United States
  • Teva Investigational Site 12101
    Seattle, Washington, United States
  • Teva Investigational Site 12109
    Spokane, Washington, United States
  • Teva Investigational Site 12044
    Tacoma, Washington, United States

Showing the first 100 of 101 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mansfield L, Yiu G, Sakov A, Liu S, Caracta C. A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma. Allergy Asthma Proc. 2017 Jul 24;38(4):264-276. doi: 10.2500/aap.2017.38.4061. Epub 2017 May 24. PubMed 28540844 ↗
  • Miller DS, Yiu G, Hellriegel ET, Steinfeld J. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. Allergy Asthma Proc. 2016 Jul;37(4):291-301. doi: 10.2500/aap.2016.37.3963. Epub 2016 May 27. PubMed 27216137 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jun 26, 2014
Start
Jul 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Apr 14, 2017
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02175771
Responsible party
Sponsor
First posted
Jun 26, 2014
Start date
Jul 2014
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Apr 14, 2017
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion